BioAdvance

Tolerance Bio is a biopharmaceutical company dedicated to extending healthspan by restoring and preserving the function of the thymus, a critical organ for immune system regulation. The company's innovative approach involves creating artificial, bio-engineered thymus tissue using induced pluripotent stem cells (iPSCs), which can then be used to establish and maintain immune tolerance in patients, potentially treating a wide range of immune-mediated diseases.

ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

KayoThera is a biotechnology company based in Princeton, New Jersey, focused on developing therapeutics for late-stage and metastatic cancers. Founded in 2019, the company aims to create first-in-class immuno- and targeted therapies that target a key enzyme responsible for protecting cancer cells, as well as depleting regulatory T-cells. This innovative approach seeks to enhance the effectiveness of existing treatments, such as chemotherapy and immunotherapy, thereby offering new hope to patients with previously incurable cancers. KayoThera's mission is centered on driving breakthroughs in cancer treatment and improving patient outcomes.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Innervace is a regenerative therapy company based in Philadelphia, Pennsylvania, focused on developing implantable tissue-engineered brain pathways to address neurodegenerative disorders. The company specializes in creating anatomically inspired living scaffolds designed for brain pathway reconstruction. Its lead clinical product is a tissue-engineered nigrostriatal pathway, which aims to replicate the lost pathway in patients with Parkinson's disease. By concentrating on the reconstruction of brain pathways rather than merely alleviating symptoms temporarily, Innervace offers innovative solutions that aim to improve the quality of life for individuals affected by these conditions. Established in 2018, the company is dedicated to advancing its products from development to commercialization.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

KayoThera is a biotechnology company based in Princeton, New Jersey, focused on developing therapeutics for late-stage and metastatic cancers. Founded in 2019, the company aims to create first-in-class immuno- and targeted therapies that target a key enzyme responsible for protecting cancer cells, as well as depleting regulatory T-cells. This innovative approach seeks to enhance the effectiveness of existing treatments, such as chemotherapy and immunotherapy, thereby offering new hope to patients with previously incurable cancers. KayoThera's mission is centered on driving breakthroughs in cancer treatment and improving patient outcomes.

Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.

Wellsheet is a technology company that enhances electronic health record (EHR) systems by organizing clinical information using machine learning. Its platform prioritizes the most relevant information for healthcare providers, facilitating quicker clinical insights and improving patient care. By integrating seamlessly with existing EHR systems, Wellsheet enables physicians to access contextualized data, which enhances efficiency and accuracy during patient interactions. The company has demonstrated its effectiveness in a large health system in New Jersey and has established partnerships with major EHR vendors to distribute its services through a software-as-a-service model. This approach allows healthcare providers to implement improvements without overhauling their current systems.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Ride Health LLC is a New York-based company that offers a software-as-a-service platform designed to improve patient access to medical appointments by managing transportation logistics. Founded in 2016, the platform enables healthcare providers to schedule, request, and pay for rides on behalf of patients, addressing transportation barriers that can hinder access to care. It allows coordinators to arrange rides in advance or on-demand, provides real-time updates and reminders to patients, and offers insights into transportation costs and usage. By partnering with healthcare organizations and transportation providers, Ride Health enhances enterprise transportation programs and supports at-risk populations, ensuring that patient needs and preferences are prioritized. This approach aims to improve efficiencies, reduce costs, and ultimately foster better healthcare outcomes.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to developing gene therapies for cardiovascular diseases. Founded in 2013, the company focuses on innovative treatments for dilated cardiomyopathy (DCM), particularly cases caused by mutations in the BAG3 gene. This condition affects over 3 million individuals in the United States, with around 35,000 patients estimated to have BAG3 mutations, classifying it as an orphan disease. Patients with BAG3-associated DCM, often younger and experiencing faster disease progression, currently have limited treatment options, primarily consisting of standard heart failure care. Renovacor's lead program involves a recombinant adeno-associated virus (AAV)-based gene therapy aimed at replacing the defective BAG3 gene, which holds the potential to prevent disease progression and improve outcomes for this vulnerable patient population.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

ENB Therapeutics is a biopharmaceutical company focused on developing small molecule inhibitors aimed at treating melanoma and other cancers. Founded in 2015 and headquartered in New York, the company’s lead product, ENB-001, is a selective endothelin B receptor (ETBR) inhibitor. This innovative therapy has shown promise in preclinical studies to reduce tumor growth and enhance survival rates in cancer models by restoring T-cell infiltration into tumors and inhibiting metastasis. ENB-001 has received Orphan Drug Designation from the FDA, ensuring market exclusivity and strong intellectual property protection. The company is also developing a companion diagnostic to identify patients with over-expressed ETBR pathways, which may allow for expansion into multiple tumor types. By addressing drug resistance commonly seen in cancer patients, ENB Therapeutics aims to establish new standards of care that enhance the effectiveness of existing immunotherapy treatments and improve patient outcomes.

Bainbridge Health, Inc. is a Philadelphia-based company that develops a clinical intelligence and data analytics platform focused on improving medication safety in hospital systems. Founded in 2016, the company provides solutions specifically for medication safety leaders, including an infusion pump management software known as InfusionWare. This platform allows clinicians to manage infusion data centrally, enhancing patient safety by streamlining data handling and reducing the likelihood of medication errors. Bainbridge Health’s vendor-agnostic approach eliminates the need for cumbersome data management practices, enabling hospitals to mitigate risks associated with medication errors while also lowering avoidable costs.

Opsidio is a biotechnology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company specializes in developing monoclonal antibodies aimed at treating fibrotic and remodeling diseases, as well as allergic conditions. Opsidio's innovative antibodies specifically target a unique form of the Stem Cell Factor, which plays a crucial role in the cascade of profibrotic cytokines. This targeted approach enables healthcare providers to address various serious conditions, including idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, ultimately improving treatment options for affected patients.

Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.

Wellsheet is a technology company that enhances electronic health record (EHR) systems by organizing clinical information using machine learning. Its platform prioritizes the most relevant information for healthcare providers, facilitating quicker clinical insights and improving patient care. By integrating seamlessly with existing EHR systems, Wellsheet enables physicians to access contextualized data, which enhances efficiency and accuracy during patient interactions. The company has demonstrated its effectiveness in a large health system in New Jersey and has established partnerships with major EHR vendors to distribute its services through a software-as-a-service model. This approach allows healthcare providers to implement improvements without overhauling their current systems.

CytoVas LLC is a life science company based in Philadelphia, Pennsylvania, that specializes in developing an innovative informatics platform, CLOUD CYTOMICS. This platform is designed to analyze flow cytometry data, providing clinicians and drug developers with actionable insights on novel cellular markers related to disease progression and individual treatment responses. By automating data collection and interpretation, CLOUD CYTOMICS enables rapid identification of cellular biomarkers, facilitating critical decision-making in the development of targeted therapies. The technology is applicable across various therapeutic areas, including cardiovascular disease, type 2 diabetes, Alzheimer’s, and more. Founded by experts in computational biology and flow cytometry from the University of Pennsylvania, CytoVas is supported by significant investments from organizations such as the American Heart Association and the National Institutes of Health, as well as a partnership with Becton Dickinson Biosciences. The company continues to explore the potential of its platform in diverse medical research fields.

Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional office in New York, New York. Founded in 2010, it specializes in providing wellness programs to healthcare providers, including rural health clinics and integrated delivery networks. The company focuses on administering Medicare Annual Wellness Visits, offering clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors, preventative goals, and measurable data. WellTrackONE supports healthcare professionals by scheduling, screening, and documenting wellness visits, while also providing critical data for accountable care organizations and helping payers maintain compliance with clinical indicators and quality measures. Through its customized wellness solutions, WellTrackONE aims to enhance patient care and improve health outcomes for Medicare patients across the United States.

Olive Devices LLC is a company based in Philadelphia, Pennsylvania, that develops innovative smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorder, early onset Alzheimer’s, and other communication or memory challenges. The smart glasses feature real-time speech-to-text captions that display in front of the user's eyes, facilitating better understanding in various settings. Additionally, Olive Devices offers a mobile application that complements the smart glasses by syncing captions to the cloud, allowing users to organize and utilize the information for note-taking and studying. The application also includes features for converting notes into memory games, tracking progress from educators, and enabling interactions between students and teachers. Founded in 2015, Olive Devices serves a diverse clientele, including teachers, students, parents, audiologists, and optometrists.

TalexMedical, LLC is a Philadelphia-based company that develops and manufactures a medical device designed to treat external ear deformities in newborns. Its primary product, Infantear, is a Class I medical device that offers a nonsurgical ear molding system. This system is applied in an outpatient setting, providing a cost-effective alternative to traditional surgical procedures. Infantear is customizable and made from soft materials, ensuring comfort for the patient. The treatment involves a straightforward two-week application during the first three weeks of life, which allows pediatricians to address ear anomalies without the need for referrals to specialists. Founded in 2015, TalexMedical aims to enhance healthcare outcomes by improving results, increasing patient satisfaction, and reducing costs.

HueDx is a developer of point-of-care diagnostic tests aimed at enhancing patient care. The company utilizes innovative paper- or wax-based microfluidics technology to deliver rapid, quantitative assay-based tests that provide quick results across a range of applications. By eliminating the need for physical devices and software, HueDx's platform streamlines the test development and launch process, making diagnostics more accessible and cost-effective. This approach not only improves transparency for clinicians but also facilitates immediate patient results, ultimately contributing to a more efficient healthcare delivery system.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Ride Health LLC is a New York-based company that offers a software-as-a-service platform designed to improve patient access to medical appointments by managing transportation logistics. Founded in 2016, the platform enables healthcare providers to schedule, request, and pay for rides on behalf of patients, addressing transportation barriers that can hinder access to care. It allows coordinators to arrange rides in advance or on-demand, provides real-time updates and reminders to patients, and offers insights into transportation costs and usage. By partnering with healthcare organizations and transportation providers, Ride Health enhances enterprise transportation programs and supports at-risk populations, ensuring that patient needs and preferences are prioritized. This approach aims to improve efficiencies, reduce costs, and ultimately foster better healthcare outcomes.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Keriton LLC is a provider of a pumped breast milk management system specifically designed for neonatal intensive care units (NICUs). Based in Philadelphia, Pennsylvania, the company offers a comprehensive platform that enhances patient safety and streamlines nursing workflows. This system enables healthcare professionals to track milk-bottle inventory, manage feeding orders, and handle first-in-first-out (FIFO) bottle flow, including notifications for expiry dates and misfeed alerts. The platform also facilitates real-time insights into lactating mothers' milk production patterns and includes a media-sharing feature for nurses to communicate with mothers by sharing photos and videos of their babies. With a track record of managing over 1.5 million feeds and preventing nearly 30,000 errors, Keriton's solution aims to improve health outcomes and reduce the cognitive burden on hospital staff. Since its incorporation in 2016, Keriton has been deployed in numerous larger enterprise health systems, demonstrating its effectiveness in enhancing the care provided to infants in NICUs.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.

Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Bainbridge Health, Inc. is a Philadelphia-based company that develops a clinical intelligence and data analytics platform focused on improving medication safety in hospital systems. Founded in 2016, the company provides solutions specifically for medication safety leaders, including an infusion pump management software known as InfusionWare. This platform allows clinicians to manage infusion data centrally, enhancing patient safety by streamlining data handling and reducing the likelihood of medication errors. Bainbridge Health’s vendor-agnostic approach eliminates the need for cumbersome data management practices, enabling hospitals to mitigate risks associated with medication errors while also lowering avoidable costs.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Olive Devices LLC is a company based in Philadelphia, Pennsylvania, that develops innovative smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorder, early onset Alzheimer’s, and other communication or memory challenges. The smart glasses feature real-time speech-to-text captions that display in front of the user's eyes, facilitating better understanding in various settings. Additionally, Olive Devices offers a mobile application that complements the smart glasses by syncing captions to the cloud, allowing users to organize and utilize the information for note-taking and studying. The application also includes features for converting notes into memory games, tracking progress from educators, and enabling interactions between students and teachers. Founded in 2015, Olive Devices serves a diverse clientele, including teachers, students, parents, audiologists, and optometrists.

Penn State Health is a multi-hospital health system that serves patients and communities across Central Pennsylvania. It includes the Milton S. Hershey Medical Center, a 551-bed Level I regional trauma center recognized for its expertise in complex adult and pediatric cases. As the region's only academic medical center, it is closely affiliated with the Penn State College of Medicine and houses the Children's Hospital at Penn State Health. The medical center has achieved ANCC Magnet Recognition, reflecting its dedication to fostering a supportive professional environment for staff and delivering high-quality patient care.

Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.

Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company develops Theo, a digital healthcare advisory platform designed to assist patients in identifying health and behavioral risks. The platform actively engages patients by providing programs and interventions to help them manage these risks. By capturing essential patient data at the time of care, Noble.MD facilitates value-based reimbursement and aligns the interests of providers and payers, enhancing the processes of risk identification, coding, and management.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

RiboNova Inc. is a biopharmaceutical company based in Wynnewood, Pennsylvania, focused on developing small molecule drugs aimed at treating serious rare diseases, including certain cancers and mitochondrial diseases. Incorporated in 2011, RiboNova leverages a drug discovery platform that targets defective transfer RNA molecules, which play a critical role in cellular function. The company's innovative approach centers on precision medicines that address ribonucleic acid anomalies, providing healthcare professionals with new treatment options for patients suffering from genetically confirmed mitochondrial conditions and select cancer types. RiboNova operates within the Lankenau Institute for Medical Research near Philadelphia, emphasizing its commitment to advancing therapeutic solutions in the field of rare diseases.

Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.

Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.

Allevi develops innovative tools for designing and engineering 3D tissues, focusing on bioprinting technology. The company offers desktop 3D bioprinters that allow users to create functional three-dimensional living tissues using various biomaterials and cell lines. Additionally, Allevi provides bioinks made from collagen and hyaluronic acid, which are available for purchase online. Their cloud-based platform, Bioprint Online, enables users to design complex structures, define materials, and monitor the printing process. Allevi's products serve a diverse clientele, including researchers in tissue engineering, regenerative medicine, and cell biology, as well as industrial and pharmaceutical companies for drug testing and development, and educators. Established in 2014 and based in Philadelphia, Pennsylvania, Allevi was formerly known as BioBots, Inc.

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional office in New York, New York. Founded in 2010, it specializes in providing wellness programs to healthcare providers, including rural health clinics and integrated delivery networks. The company focuses on administering Medicare Annual Wellness Visits, offering clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors, preventative goals, and measurable data. WellTrackONE supports healthcare professionals by scheduling, screening, and documenting wellness visits, while also providing critical data for accountable care organizations and helping payers maintain compliance with clinical indicators and quality measures. Through its customized wellness solutions, WellTrackONE aims to enhance patient care and improve health outcomes for Medicare patients across the United States.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

HealthQX, founded in 2012 and based in King of Prussia, Pennsylvania, specializes in value-based payment analytic software solutions tailored for health plans and providers. The company's primary offering, ClarityQx, is a comprehensive analytics platform designed to facilitate the design, implementation, and ongoing performance monitoring of various payment models, including episodic, bundled, and accountable care arrangements. This platform provides users with drill-down dashboards that enhance provider engagement and streamline contract negotiation processes. By enabling quick access to critical payment analytics, HealthQX aims to improve consumer care and reduce medical costs within the healthcare industry.

TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses​ to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. Established in 2004, the company is primarily working on its lead product candidate, d-Methadone, which is undergoing Phase II clinical trials for conditions such as major depressive disorder and neuropathic pain. In addition to d-Methadone, Relmada is developing LevoCap ER, a sustained-release formulation of levorphanol designed to be abuse-resistant; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine intended for localized anesthesia. The company's research aims to address significant unmet medical needs in CNS disorders and improve patient outcomes.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. Established in 2004, the company is primarily working on its lead product candidate, d-Methadone, which is undergoing Phase II clinical trials for conditions such as major depressive disorder and neuropathic pain. In addition to d-Methadone, Relmada is developing LevoCap ER, a sustained-release formulation of levorphanol designed to be abuse-resistant; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine intended for localized anesthesia. The company's research aims to address significant unmet medical needs in CNS disorders and improve patient outcomes.

BioDetego is focused on advancing cancer treatment through its innovative biomarker test, VASPfore, which is designed to optimize the selection of chemotherapy protocols. This test assesses the metastatic risk in colorectal cancer patients, allowing healthcare providers to identify high-risk individuals who are likely to benefit from chemotherapy while sparing low-risk patients from unnecessary and potentially harmful treatments. By providing actionable insights, VASPfore aims to improve patient outcomes and enhance the efficiency of cancer management. BioDetego anticipates significant cost savings for payors, estimating reductions of over $150 million annually in treatment expenses. The company is led by David Zuzga, Ph.D., and Giovanni M. Pitari, M.D., Ph.D., both of whom bring extensive expertise in cell and molecular biology and translational oncology, respectively.

HealthQX, founded in 2012 and based in King of Prussia, Pennsylvania, specializes in value-based payment analytic software solutions tailored for health plans and providers. The company's primary offering, ClarityQx, is a comprehensive analytics platform designed to facilitate the design, implementation, and ongoing performance monitoring of various payment models, including episodic, bundled, and accountable care arrangements. This platform provides users with drill-down dashboards that enhance provider engagement and streamline contract negotiation processes. By enabling quick access to critical payment analytics, HealthQX aims to improve consumer care and reduce medical costs within the healthcare industry.

InfraScan, Inc. is a medical device company that specializes in developing and distributing hand-held diagnostic devices for assessing head injuries and strokes using near-infrared (NIR) technology. Its primary product, the Infrascanner, allows healthcare professionals to detect intracranial bleeding in patients with head trauma, which is crucial for timely intervention. The device is applicable in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan was founded in 2004 and is headquartered in Philadelphia, Pennsylvania, where it also operates a research and development lab. The company markets its products through a network of distributors across North America, South America, Africa, Asia, the Middle East, and Europe.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.

Annovis Bio, Inc. is a clinical-stage pharmaceutical company based in Berwyn, Pennsylvania, specializing in the development of treatments for neurodegenerative disorders, particularly Alzheimer's disease and Parkinson's disease. The company is advancing several compounds in clinical trials, with its lead candidate, ANVS401, currently in Phase 2a trials aimed at treating Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. Additionally, Annovis is developing ANVS405, which focuses on providing neuroprotection following traumatic brain injuries and strokes, and ANVS301, which is in Phase I trials designed to enhance cognitive function in later stages of Alzheimer’s disease and dementia. Founded in 2008, Annovis Bio is dedicated to creating innovative therapies to address the challenges posed by these debilitating diseases.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Life Mist Technologies, Inc., based in Paoli, Pennsylvania, specializes in developing and commercializing an innovative atomization technology that generates a high volume of micron-sized droplets using low-pressure gas and liquid. This technology is designed for a diverse array of industrial applications, including aircraft fire suppression, chemical processing, emission control, turbine inlet cooling, and decontamination. Additionally, it serves sectors such as artificial snow production and cooling systems. By leveraging its unique atomization capabilities, Life Mist Technologies aims to enhance existing processes and provide effective solutions to various industrial challenges. The company has been operational since its incorporation in 2004.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Niiki Pharma is a development-focused oncology company that specializes in creating first-in-class cancer treatments aimed at novel cellular targets, along with related companion diagnostics. The company is committed to advancing innovative therapies to improve cancer care, leveraging a team of experts in cancer drug development and commercialization. Niiki Pharma emphasizes quality, speed, and capital efficiency in its programs, positioning itself as a key player in the oncology sector.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.

Anakim Biologics is developing efficiencies and improvements in biologics manufacturing.

Treventis Corporation specializes in developing small molecule drugs aimed at treating and preventing protein misfolding diseases, particularly focusing on tauopathies related to Alzheimer’s disease. The company employs a proprietary discovery engine called Common Conformational Morphology (CCM), which integrates advanced in silico modeling with extensive expertise in drug development across various biological systems. This innovative approach allows Treventis to identify druggable active sites in misfolded protein targets, facilitating the rational design of therapeutic compounds. The lead program is centered around anti-misfolding small molecules that target tau proteins, while additional CCM-driven initiatives are underway in oncology and other neurodegenerative disorders, highlighting the versatility of their technology platform. The drugs developed by Treventis aim to effectively neutralize misfolded proteins, potentially blocking the progression of amyloid toxicity and offering a treatment option for Alzheimer’s patients with minimal side effects.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. Established in 2004, the company is primarily working on its lead product candidate, d-Methadone, which is undergoing Phase II clinical trials for conditions such as major depressive disorder and neuropathic pain. In addition to d-Methadone, Relmada is developing LevoCap ER, a sustained-release formulation of levorphanol designed to be abuse-resistant; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine intended for localized anesthesia. The company's research aims to address significant unmet medical needs in CNS disorders and improve patient outcomes.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.

Imiplex LLC is a biotechnology company based in Bristol, Pennsylvania, that specializes in developing protein-based nanotechnology for applications in biosensors, biomaterials, and targeted therapeutic and diagnostic agents. Founded in 2003, Imiplex has created a platform known as TriPol, which consists of modular components engineered from proteins. This technology leverages the unique properties of proteins, such as their ability to self-assemble with atomic precision and their structural diversity, to construct various nanostructures. These engineered protein nanostructures support early diagnosis and treatment of diseases, including cancer, diabetes, and neurodegenerative disorders like Alzheimer's disease.

COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.

CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.